原发性肝癌治疗的研究进展
Research Progress in the Treatment of Primary Hepatic Carcinoma
DOI: 10.12677/ACM.2022.12121583, PDF,   
作者: 曹沐筝*, 石攀成, 李 枫, 张道峰, 李 凡, 王登基, 叶哓琳, 谢国伟：青海大学，青海 西宁；王哓临#：青海大学附属医院，青海 西宁
关键词: 原发性肝癌；治疗；研究进展；Primary Hepatic Carcinoma； Treatment； Research Progress
摘要: 原发性肝癌(primary hepatic carcinoma, PHC)，简称肝癌，是临床上常见的消化系统恶性肿瘤之一。目前，原发性肝癌的治疗手段包括手术治疗和非手术治疗。文章就原发性肝癌的不同治疗方法进行概述，为临床治疗原发性肝癌提供参考。
Abstract: Primary hepatic carcinoma (PHC), referred to as liver cancer, is one of the common malignant tu-mors of digestive system in clinic. At present, the treatment of primary liver cancer includes surgi-cal treatment and non-surgical treatment. This article summarized the different treatment meth-ods of primary liver cancer, and provided reference for clinical treatment of primary liver cancer.
文章引用：曹沐筝, 王哓临, 石攀成, 李枫, 张道峰, 李凡, 王登基, 叶哓琳, 谢国伟. 原发性肝癌治疗的研究进展[J]. 临床医学进展, 2022, 12(12): 10994-11000. https://doi.org/10.12677/ACM.2022.12121583

参考文献

[1] Freddie, B., et al. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA—A Cancer Journal for Clinicians, 68, 394-424. [Google Scholar] [CrossRef] [PubMed]
[2] 赵文江, 张晓磷, 赵苗. 原发性肝癌肺转移的治疗进展[J]. 海南医学, 2018, 29(1): 87-90.
[3] 杨婉婷, 侯恩存. 原发性肝癌治疗的研究进展[J]. 现代肿瘤医学, 2016, 24(21): 3495-3499.
[4] 卢绪信. 原发性肝癌的治疗进展[J]. 中外医学研究, 2018, 16(2): 177-179.
[5] Tang, A., Hal-louch, O., et al. (2018) Epidemiology of Hepatocellular Carcinoma: Target Population for Surveillance and Diagnosis. Abdominal Radiology (NY), 43, 13-25. [Google Scholar] [CrossRef] [PubMed]
[6] Bruix, J., Reig, M. and Sherman, M. (2016) Evidence-Based Diagnosis, Staging, and Treatment of Patients with Hepatocellular Carcinoma. Gastroenterology, 150, 835-853. [Google Scholar] [CrossRef] [PubMed]
[7] Choti, M.A., Thomas, M., Wong, S.L., et al. (2016) Surgical Resection Preferences and Perceptions among Medical Oncologists Treating Liver Metastases from Colorectal Cancer. Annals of Surgical Oncology, 23, 375-381. [Google Scholar] [CrossRef] [PubMed]
[8] Kanwal, F. and Singal, A.G. (2019) Surveillance for Hepatocellu-lar Carcinoma: Current Best Practice and Future Direction. Gastroenterology, 157, 54-64. [Google Scholar] [CrossRef] [PubMed]
[9] Fujiwara, N., Friedman, S.L., Goossens, N. and Hoshida, Y. (2018) Risk Factors and Prevention of Hepatocellular Carcinoma in the Era of Precision Medicine. Journal of Hepatology, 68, 526-549. [Google Scholar] [CrossRef] [PubMed]
[10] Gunsar, F. (2017) Liver Transplantation for Hepatocellular Carci-noma Beyond the Milan Criteria. Experimental and Clinical Transplantation, 15, 59-64.
[11] Kardashian, A., Florman, S.S., Haydel, B., et al. (2020) Liver Transplantation Outcomes in a U.S. Multicenter Cohort of 789 Patients with Hepa-tocellular Carcinoma Presenting beyond Milan Criteria. Hepatology, 72, 2014-2028.
[12] Bodzin, A.S. and Baker, T.B. (2018) Liver Transplantation Today: Where We Are Now and Where We Are Going. Liver Transplantation 24, 1470-1475. [Google Scholar] [CrossRef] [PubMed]
[13] Miller, C.M., Quintini, C., Dhawan, A., et al. (2017) The Interna-tional Liver Transplantation Society Living Donor Liver Transplant Recipient Guideline. Transplantation, 101, 938-944. [Google Scholar] [CrossRef] 
[14] 王峰, 饶伟, 臧运金. 肝癌肝移植的研究现状和进展[J]. 临床外科杂志, 2017, 25(3): 165-168.
[15] Raoul, J.L., Forner, A., Bolondi, L., Cheung, T.T., Kloeckner, R. and de Baere, T. (2019) Updated Use of TACE for Hepatocellular Carcinoma Treatment: How and When to Use It Based on Clinical Evidence. Cancer Treatment Reviews, 72, 28-36. [Google Scholar] [CrossRef] [PubMed]
[16] Yoon, S.M., Ryoo, B.Y., Lee, S.J., et al. (2018) Efficacy and Safety of Transarterial Chemoembolization plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma with Macroscopic Vascular Invasion: A Randomized Clinical Trial. JAMA Oncology, 4, 661-669. [Google Scholar] [CrossRef] [PubMed]
[17] Galle, P.R., Tovoli, F., Foerster, F., Wörns, M.A., Cucchetti, A. and Bolondi, L. (2017) The Treatment of Intermediate Stage Tumours beyond TACE: From Surgery to Systemic Therapy. Journal of Hepatology, 67, 173-183. [Google Scholar] [CrossRef] [PubMed]
[18] Monier, A., Guiu, B., Duran, R., et al. (2017) Liver and Biliary Damages Following Transarterial Chemoembolization of Hepatocellular Carcinoma: Comparison between Drug-Eluting Beads and Lipiodol Emulsion. European Radiology, 27, 1431-1439. [Google Scholar] [CrossRef] [PubMed]
[19] Kudo, M., Ueshima, K., Ikeda, M., et al. (2020) Randomised, Multicentre Prospective Trial of Transarterial Chemoembolisation (TACE) plus Sorafenib as Compared with TACE Alone in Patients with Hepatocellular Carcinoma: TACTICS Trial. Gut, 69, 1492-1501. [Google Scholar] [CrossRef] [PubMed]
[20] Xu, X.L., Liu, X.D., Liang, M. and Luo, B.M. (2018) Radiofre-quency Ablation versus Hepatic Resection for Small Hepatocellular Carcinoma: Systematic Review of Randomized Con-trolled Trials with Meta-Analysis and Trial Sequential Analysis. Radiology, 287, 461-472. [Google Scholar] [CrossRef] [PubMed]
[21] Izzo, F., Granata, V., Grassi, R., et al. (2019) Radiofrequency Ab-lation and Microwave Ablation in Liver Tumors: An Update. Oncologist, 24, e990-e1005. [Google Scholar] [CrossRef] [PubMed]
[22] Han, J., Fan, Y.C. and Wang, K. (2020) Radiofrequency Ablation versus Microwave Ablation for Early Stage Hepatocellular Carcinoma: A PRISMA-Compliant Systematic Re-view and Meta-Analysis. Medicine (Baltimore), 99, e22703. [Google Scholar] [CrossRef] 
[23] Rra, B., et al. (2019) Immune Mechanisms Mediating Ab-scopal Effects in Radioimmunotherapy. Pharmacology & Therapeutics, 196, 195-203. [Google Scholar] [CrossRef] [PubMed]
[24] Yang, C., Wang, Q., Liu, X., et al. (2016) NU7441 En-hances the Radiosensitivity of Liver Cancer Cells. Cellular Physiology and Biochemistry, 38, 1897-1905. [Google Scholar] [CrossRef] [PubMed]
[25] Assenat, E., Pageaux, G.P., Thézenas, S., et al. (2019) Sorafenib Alone vs. Sorafenib Plus GEMOX as 1st-Line Treatment for Advanced HCC: The Phase II Randomised PRODIGE 10 Trial. Brit-ish Journal of Cancer, 120, 896-902. [Google Scholar] [CrossRef] [PubMed]
[26] Zhou, J., Sun, H., Wang, Z., et al. (2020) Guidelines for the Di-agnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer, 9, 682-720.
[27] Pressiani, T., Boni, C., Rimassa, L., et al. (2013) Sorafenib in Patients with Child-Pugh Class A and B Advanced Hepatocellular Carcinoma: A Prospective Feasibility Analysis. Annals of Oncology, 24, 406-411. [Google Scholar] [CrossRef] [PubMed]
[28] 王程, 王宁菊. 索拉菲尼治疗晚期原发性肝癌患者的临床疗效及毒副反应观察[J]. 宁夏医学杂志, 2015, 37(12): 1139-1140.
[29] 杨家进. 索拉菲尼治疗耐受TACE的晚期原发性肝癌患者疗效分析[D]: [硕士学位论文]. 南昌: 南昌大学, 2016.
[30] Bruix, J., Qin, S., Merle, P., et al. (2017) Regorafenib for Patients with Hepatocellular Carcinoma Who Progressed on Sorafenib Treatment (RESORCE): A Ran-domised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet, 389, 56-66. [Google Scholar] [CrossRef] 
[31] 倪洪波. 肝癌治疗的新进展[J]. 中国肿瘤临床与康复, 2014, 21(9): 1148-1150.
[32] Sprinzl, M.F. and Galle, P.R. (2017) Current Progress in Immunotherapy of Hepatocellu-lar Carcinoma. Journal of Hepatology, 66, 482-484. [Google Scholar] [CrossRef] [PubMed]
[33] 王正, 王明达, 李镇利, 杨田. 肝癌免疫治疗的研究进展和临床展望[J]. 第二军医大学学报, 2017, 38(8): 953-960.
[34] Liu, C., Yang, S., Wang, K., et al. (2019) Alkaloids from Traditional Chinese Medicine against Hepatocellular Carcinoma. Bio-medicine & Pharmacotherapy, 120, Article ID: 109543. [Google Scholar] [CrossRef] [PubMed]
[35] Liu, X.L., et al. (2019) Effects of Adjuvant Traditional Chinese Medicine Therapy on Long-Term Survival in Patients with Hepatocellular Carcinoma. Phytomedicine, 62, Article ID: 152930. [Google Scholar] [CrossRef] [PubMed]
[36] Yang, Y., Sun, M., Yao, W., et al. (2020) Compound Kushen Injection Relieves Tumor-Associated Macrophage-Mediated Immunosuppression through TNFR1 and Sensitizes Hepa-tocellular Carcinoma to Sorafenib. The Journal for ImmunoTherapy of Cancer, 8, e000317. [Google Scholar] [CrossRef] [PubMed]

为你推荐